

# Acanya<sup>®</sup> Gel Instant Savings Card Extended to August 31, 2009

All cards with June or July printed expiration dates are  
now valid through August 31, 2009

**Pay \$0 for your first  
prescription\***

**Acanya Gel**   
(Clindamycin Phosphate 1.2%  
and Benzoyl Peroxide 2.5%)

**Instant Savings**

**\$0 Co-Pay\***  
for most patients

This offer expires June 15, 2009

Original  
expiration  
date; now  
valid through  
8/31/09

Present this card to your pharmacist along  
with your prescription for Acanya<sup>™</sup> Gel.

**BIN: 610020**  
**GROUP: 99990935**  
**MEMBER: 12345678901**

\*With this card, your initial out-of-pocket expense for Acanya Gel may be zero dollars. This offer is good for a maximum of \$100 off your co-pay or off the full prescription cost of one 50g jar of Acanya Gel if the eligibility terms and conditions on reverse are met.

**Pharmacists: For questions, please call 1-866-954-1484**

If you would like to opt out of future PDQ Communications Flash Fax broadcasts, please call 888-218-2474, and input your fax number

Re: Return of Yellow-Square Mysoline® (primidone, USP) 250 mg tablets  
Date: June 29, 2009

Dear Pharmacist,

We are writing to inform you that Valeant is now able to reintroduce the previous formulation/presentation of yellow-square Mysoline 250 mg tablets. You may have noticed that for the past year, Valeant had switched to a temporary version of branded Mysoline 250 mg tablets, presented as a white-round tablet manufactured by Watson Laboratories. From this point forward, the yellow-square version will be the only branded version of Mysoline 250 mg tablets manufactured. There will, however, be a brief transition overlap period during which both the white-round 250 mg tablet and yellow-square 250 mg tablet may both be available in pharmacies. Following this period, only the yellow-square 250 mg tablet will be available as Mysoline 250 mg tablets.

Mysoline tablets are indicated in the control of grand mal, psychomotor and focal epileptic seizures.

Listed below is important information regarding this change to Mysoline 250 mg tablets:

- Temporarily presented (for approximately the past year) as white-round tablets, Mysoline 250 mg will once again be presented as a yellow-square shaped tablet
- The bottle will be in Valeant trade packaging, will include the call out: "Original Tablet Design" on the bottle, and will also feature a picture of the yellow-square tablet
- The NDC number 66490-691-10 will remain unchanged
- FDA has reviewed and approved this change

The current changes in manufacturing affect the Mysoline 250 mg tablets only, and production of Mysoline 50 mg tablets remains unaffected by the changes outlined above.

As is customary, when any changes occur with anticonvulsant therapy, we suggest that patients receive additional counseling from their physicians.

If your patients are seeking additional information on this issue, we have established a website at [www.valeant.com/mysoline](http://www.valeant.com/mysoline) to further address their (or your) questions. Questions may also be directed to Valeant's Customer Service team at 800-556-1937.

Valeant is committed to maintaining the very highest quality standards for the medications we offer in epilepsy care, and is pleased to be able to re-release this original formulation of Mysoline 250 mg tablets.

Sincerely,



Janet MJ Hammond, MD, PhD, ScM  
Chief Medical Officer and VP Global Medical Affairs  
North America, Research and Development  
Valeant Pharmaceuticals International

If you would like to opt out of future PDQ Communications Flash Fax broadcasts, please call 888-218-2474, and input your fax number